 Akero Therapeutics Inc NASDAQ: AKRO has announced additional analyses from its Phase 2a BALANCED study of efruxifermin EFX in non-alcoholic steatohepatitis NASH patients with F1-F3 fibrosis. Data were presented at the 2021 International Liver Congress. 